Výsledky vyhledávání - "Ekaterina Gibiansky"

Akademický článek

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

Autor: Ekaterina Gibiansky, Leonid Gibiansky, Clarisse Chavanne, Nicolas Frey, Candice Jamois

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 914-927 (2021)

Abstract A subcutaneous formulation of the anti‐CD20 antibody rituximab has been developed. Fixed‐dose subcutaneous rituximab delivers noninferior serum trough concentrations (Ctrough), ensuring similar target saturation and comparable efficacy/s

Externí odkaz: https://doaj.org/article/96de8a1a1020405cb52160c9fa76dd90

Zobrazit plný text záznamu

Plný text ve formátu HTML

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia

Autor: Leonid Gibiansky, Ekaterina Gibiansky, Candice Jamois, Clarisse Chavanne, Nicolas Frey

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 914-927 (2021)
CPT: Pharmacometrics & Systems Pharmacology

A subcutaneous formulation of the anti-CD20 antibody rituximab has been developed. Fixed-dose subcutaneous rituximab delivers non-inferior serum trough concentrations (Ctrough ), ensuring similar target saturation and comparable efficacy/safety to in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::843b8eb780224e875f40414e6ba6215c
https://doaj.org/article/96de8a1a1020405cb52160c9fa76dd90

Zobrazit plný text záznamu

Plný text ve formátu HTML

Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies

Autor: Artem Zharkov, Axel Boehnke, Christine McIntyre, Peter N. Morcos, Linda Lundberg, Ekaterina Gibiansky, Martin Barrett, Clarisse Chavanne, Nicolas Frey, Candice Jamois, Leonid Gibiansky

Publikováno v: Clinical Pharmacology and Therapeutics

A fixed-dose subcutaneous (s.c.) formulation of the anti-CD20 antibody, rituximab, has been developed to address safety, infusion time, and patient comfort concerns relating to intravenous (i.v.) dosing, and has been approved based upon a pharmacokin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52c164e0ad6704b1beef5f061f4e2a51
http://europepmc.org/articles/PMC8597022

Zobrazit plný text záznamu

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

Autor: Fabian Model, Ludwig Kappos, Stephen L. Hauser, Heidemarie Kletzl, Ekaterina Gibiansky, Andreas Günther, Claire Petry, Ann Herman, Francois Mercier, Yumi Yamamoto, Qing Wang

Publikováno v: British Journal of Clinical Pharmacology
British journal of clinical pharmacology, vol 87, iss 6

AimsOcrelizumab is a humanized monoclonal antibody that selectively targets CD20-positive B cells and is indicated for treatment of patients with relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The pharma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8811580eb5543d689634ed86d7b68a05
http://europepmc.org/articles/PMC8247316

Zobrazit plný text záznamu

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study

Autor: Günter Fingerle-Rowson, Ekaterina Gibiansky, Michael Brewster, Vincent Buchheit, Candice Jamois, Nicolas Frey, Leonid Gibiansky

Publikováno v: British Journal of Clinical Pharmacology

Aims Rituximab is standard care in a number of lymphoma subtypes, including follicular lymphoma (FL), although many patients are resistant to rituximab, or develop resistance with repeated treatment, and a high proportion relapse. Obinutuzumab is a n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4b4b5b9e79dadd4607773fd9f466ae0
https://doi.org/10.1111/bcp.13974

Zobrazit plný text záznamu

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis

Autor: Ekaterina Gibiansky, Xiaofeng Wang, Suresh Mallikaarjun

Publikováno v: Antimicrobial Agents and Chemotherapy

A population pharmacokinetic (PopPK) model of delamanid in patients with pulmonary multidrug-resistant tuberculosis (MDR-TB) was developed using data from four delamanid clinical trials. The final PopPK data set contained 20,483 plasma samples from 7

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75f7f56f5f2a2a3b1110e167a30acf1a
http://europepmc.org/articles/PMC7927850

Zobrazit plný text záznamu

Assessing Romiplostim Dose and Platelet Response-Guided Titration to Support Use of Romiplostim in ITP Patients Less Than 12 Months from Diagnosis

Autor: Ekaterina Gibiansky, Sameer Doshi, Vincent Chow, Hossam A Saad, Florencio Serrano Castillo

Publikováno v: Blood. 138:4221-4221

Background: Romiplostim, a subcutaneous treatment for adult ITP, uses a platelet response-guided dose adjustment algorithm (USPI dosing, Table 1) to maintain patients' platelet count (PC). Romiplostim was recently approved for patients with ITP ≤ 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95307cdd48db6a8e08a8214aa2ea0e56
https://doi.org/10.1182/blood-2021-153066

Zobrazit plný text záznamu

Tutorial: Numerical (NONMEM) Implementation of the Target-Mediated Drug Disposition Model

Autor: Ekaterina Gibiansky, Leonid Gibiansky

Publikováno v: Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases ISBN: 9781119289234
Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::888b5ffa8bb408674d5644adaf869957
https://doi.org/10.1002/9781119289234.ch8

Zobrazit plný text záznamu

Modeling Approaches to Characterize Target-Mediated Pharmacokinetics and Pharmacodynamics for Therapeutic Proteins

Autor: Ekaterina Gibiansky, Leonid Gibiansky

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74731c14195a60ec7b17c837b23a87b2
https://doi.org/10.1002/9781119289234.ch7

Zobrazit plný text záznamu

Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites

Autor: Ekaterina Gibiansky, Leonid Gibiansky

Publikováno v: Journal of pharmacokinetics and pharmacodynamics. 45(1)

The emerging discipline of mathematical pharmacology occupies the space between advanced pharmacometrics and systems biology. A characteristic feature of the approach is application of advance mathematical methods to study the behavior of biological

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac7d92f8d7fd6477bc3cc3deb87203b2
https://pubmed.ncbi.nlm.nih.gov/28918570

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání